Who is sponsoring NCT00115245?

NCT00115245 is sponsored by Novartis.

What condition does NCT00115245 study?

NCT00115245 studies Chronic Hepatitis B.

What drugs are being tested in NCT00115245?

Interventions: Telbivudine (LdT), Adefovir Dipivoxil.

What is the status of NCT00115245?

NCT00115245 is currently COMPLETED.

Last reviewed 2015-05-08 · How we verify

A Randomized, Open-Label Trial of Telbivudine Versus Adefovir Dipivoxil in Adults With HBegAg-Positive, Compensated Chronic Hepatitis B

NCT00115245 Phase 3 COMPLETED

This research study is being conducted to compare the safety and effectiveness of the investigational medication, LdT (telbivudine) versus adefovir dipivoxil, a drug approved by the Food and Drug Administration (FDA) for the treatment of hepatitis B infection. The results for patients taking LdT will be compared to results for patients taking adefovir dipivoxil.

Details

Lead sponsor	Novartis
Phase	Phase 3
Status	COMPLETED
Start date	2004-11
Completion	2006-08

Conditions

Chronic Hepatitis B

Interventions

Telbivudine (LdT)
Adefovir Dipivoxil

Countries

United States, Australia, Canada, China, France, Singapore, South Korea, Taiwan, Thailand